19.7.2004: Meldung: Bayer Healthcare is sponsor of the San Francisco AIDS Walk
The 6.2-mile Bay area AIDS Walk is one of more than 75 walks happening in cities around the globe. In 2003, more than 25,000 participants from the San Francisco area helped raise in excess of $3.1 million for the San Francisco AIDS Foundation and 36 other local AIDS service organizations. This year""s event will be held July 18, 2004 in Golden Gate Park and, for the first time in the event""s history, will offer parents, children and families the opportunity to picnic, play and socialize in a dedicated area called KidZone. Compliments of Bayer HealthCare, KidZone will feature games and fun-filled events for children including clowns, face painting and other festivities for young adults. More than 2,000 families are expected to participate in KidZone.
Dr. Hans Hiller, Head of Bayer HealthCare""s Diagnostics Professional Testing Systems, commented on Bayer""s support of this event: "At Bayer HealthCare, we believe that leadership is synonymous with responsibility. It is our duty as a global healthcare leader to give back to -- and invest in -- the local communities we serve around the world. With such forward-thinking research and development efforts targeted at HIV and AIDS, we are proud to participate in this event and enable the organization to deliver a family oriented activity for the San Francisco Community."
Paul Heiden, Sr. Vice President of Bayer Biological Products and Bayer Berkeley site manager had this to add: "Throughout its history, the Bayer group in Berkeley has demonstrated a high level of commitment to community support through charitable contributions and active employee participation in efforts such as the AIDS Walk. We are proud to offer our help for this worthy cause."
Bayer HealthCare, Diagnostics is a leader in developing and marketing innovative tests for infectious diseases, including HIV. Its VERSANT(R) HIV-1 RNA 3.0 assay, as well as its TRUGENE(R) HIV-1 Genotyping Test, leverage state-of-the-art technologies that enable laboratories, clinicians and physicians to monitor and direct treatment for patients living with HIV infection.
For more than 60 years, scientists and researchers at Bayer HealthCare, Biological Products have been dedicated to developing and producing novel treatments that extend and enhance the lives of patients who suffer from life-threatening diseases, such as hemophilia, alpha1-antitrypsin deficiency, and a variety of immune diseases. At their world-class biotechnology facility in Berkeley, Calif., Bayer BP manufactures Kogenate(R) FS Antihemophilic Factor (Recombinant), Formulated with Sucrose, a recombinant factor VIII treatment for hemophilia A that offers a more convenient administration by utilizing a 2.5 mL diluent, the smallest among available factor VIII products.
About the San Francisco AIDS Foundation
Through its comprehensive array of critical services such as treatment support, housing assistance, client advocacy and the California AIDS Hotline (800.367.AIDS), SFAF annually serves 120,000 individuals affected each year by HIV and AIDS. The non-profit community-based organization reaches over 1.5 million others through community outreach, advocacy efforts, prevention campaigns and through the web at http://www.sfaf.org/, http://www.gaylife.org/, and http://www.aidshotline.org/.
About Bayer HealthCare AG
Bayer HealthCare AG, a subgroup of Bayer AG with sales of approximately euro 8.9 billion in 2003 is one of the world""s leading, innovative companies in the health care and medical products industry.
The company combines the global activities of the divisions Animal Health, Biological Products, Consumer Care, Diagnostics and Pharmaceuticals. More than 34,000 people are employed by Bayer HealthCare worldwide.
Our aim is to discover and manufacture innovative products that will improve human and animal health worldwide. Our products enhance well-being and quality of life by diagnosing, preventing and treating disease.
This news release contains forward-looking statements based on current assumptions and forecasts made by Bayer Group management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in our public reports filed with the Frankfurt Stock Exchange and with the U.S. Securities and Exchange Commission (including our Form 20-F). The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.
Bayer HealthCare LLC